ABIONYX Pharma 2025 half-year review

ABIONYX Pharma, an innovative biotechnology company, has presented its results for the first half of 2025. The group focuses on therapies for sepsis and Norum disease, but did not generate any direct revenue. Consolidated sales reached €2.1 million, thanks to its subsidiary IRIS Pharma, which specializes in ophthalmology. The company has €3.4 million in cash, including a tax credit refund. ABIONYX received €8.7 million in government funding for a sepsis project, with another €7 million to be received, guaranteeing its financial visibility until the end of 2026.